Lundbeck Q3 2019 Financial Results
Lu AF28996: A potentially highly efficacious oral treatment for
Parkinson's patients experiencing motor fluctuations
*
Lu AF28996 is highly potent
agonist at the D₁- and D₂-type
dopamine receptors
D₁/D₂-type agonists are known
to be highly efficacious even in
the later stages of Parkinson's,
but the currently available
agonist (apomorphine) cannot
be delivered by oral route
Parkinson's disease (moderate to
advanced) as adjunct to L-DOPA
(or monotherapy pending data)
I
Ongoing phase I study1:
*
*
Single- and sequential-
ascending-dose of Lu AF28996
to healthy young men
-20 participants
Open-label study investigating
the safety, tolerability and
pharmacokinetic profile of Lu
AF28996
Study initiated in May 2018
35
1) NCT03565094
LundbeckView entire presentation